FDA Greenlights Four Revised COVID-19 Vaccines for the 2026–27 Season

Buzzline

The FDA has granted approval for four revised COVID-19 vaccines intended for the 2026–2027 season, specifically targeting the JN.1-lineage XFG variant. This group includes two products from Moderna, one from Novavax-Sanofi, and another from Pfizer-BioNTech. All four vaccines are authorized for adults aged 65 and above, while access for younger individuals is contingent on their health status and the specific vaccine received. These updated vaccines are already being distributed at select pharmacies, although the CDC's recommendations for the upcoming fall season are still pending. Prior CDC data indicated that the vaccines for the 2023–2024 season lowered the risk of severe illness by 70% among adults aged 18 and older. Disclosure:This video contains stock footage and content created or enhanced using Ai-assisted tools ai-generated

Transcript

00:00FDA has approved four updated COVID-19 vaccines for the 2026-2027 season.

00:07The vaccines are designed to target the circulating JN, one-lineage XFG variant.

00:12Two updated vaccines come from Moderna, with one each from Novavax, Sanofi, and Pfizer-BioNTech.

00:18All four vaccines are approved for adults age 65 and older.

00:22Younger people may also qualify if they have underlying conditions.

00:26The updated shots are already available at some U.S. pharmacies.

00:30However, the CDC has not yet issued its updated fall vaccination recommendations.

00:35That could affect vaccine access and insurance coverage in some cases.

00:38Previous CDC data found a 70% reduction in critical illness risk.

00:43That figure came from adults who received the 2023-2024 vaccines.

00:48Experts say it is still too early to measure the effectiveness of the new shots.

00:52The American Academy of Pediatrics also recommends vaccination for certain children.

00:57More guidance is expected as the fall vaccination season develops.

01:01Disclosure.

01:02This video contains stock footage and content created or enhanced using AI-assisted tools.

01:06Disclosure.

Category

Transcript

Comments

Recommended